Unknown

Dataset Information

0

Raising the bar: the future of EGFR inhibition in non-small lung cancer.

ABSTRACT:

SUBMITTER: Redig AJ 

PROVIDER: S-EPMC5750143 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Raising the bar: the future of EGFR inhibition in non-small lung cancer.

Redig Amanda J AJ  

Translational lung cancer research 20171201 Suppl 1

Similar Datasets

Unknown Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
| S-EPMC4466647 | biostudies-literature
Unknown Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
| S-EPMC3862576 | biostudies-literature
Unknown EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
| S-EPMC549608 | biostudies-literature
Unknown Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations.
| S-EPMC9712740 | biostudies-literature
Unknown Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.
| S-EPMC10532491 | biostudies-literature
Unknown Inhibition of primary ciliogenesis enhances efficacy of EGFR‑TKIs against non‑small cell lung cancer cells.
| S-EPMC12710141 | biostudies-literature
Unknown The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.
| S-EPMC8600554 | biostudies-literature
Unknown CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.
| S-EPMC7169661 | biostudies-literature
Unknown Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer.
| S-EPMC8048518 | biostudies-literature
Unknown Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
| S-EPMC8395077 | biostudies-literature